New Drug Combinations Show Promise for Patients With Relapsed/Refractory Neuroblastoma
Two novel regimens showed significant anti-tumor activity in patients with neuroblastoma.
Diagnosis & Disease Information
Analysis Reveals Potentially Targetable Fusion Genes in Various Cancer Types
An RNA assay for common gene fusions is now validated and available to guide patients with cancer to clinical trials and through drug treatment options.
Clinical Benefit for Patients When Treated Based on ctDNA Findings
Nearly half of patients with advanced cancer treated with FDA-approved therapies had alterations in circulating tumor DNA (ctDNA).
Serum Carbonic Anhydrase IV Predictive of Bevacizumab Efficacy in Breast Cancer
Serum levels of carbonic anhydrase IV (sCAIX) were associated with improved pathologic complete response rates.
Single-cell RNA-sequencing Can Resolve Malignant, Non-malignant Heterogeneity
Single-cell RNA-sequencing can resolve the heterogeneity of both malignant and non-malignant tumor components.
Funding, Informatics System, Clinical Data Capture Among Barriers to Effective Data Sharing
Funding, informatics system, clinical data capture, and European data protection legislation were considered the greatest barriers to effective data sharing.
Biosimilar to Trastuzumab Comparable in Efficacy, Safety for Advanced HER2+ Breast Cancer
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
Substituting Nab-paclitaxel in Anthracycline Regimen Did Not Significantly Improve pCR in HER2-negative Breast Cancer
Replacing paclitaxel with nab-paclitaxel in an anthracycline regimen failed to significantly improve the pathologic complete response rate.
Study Evaluates Adding, Substituting Neoadjuvant Lapatinib for HER2+ Breast Cancer
Adding lapatinib to trastuzumab plus weekly paclitaxel after an anthracycline was not beneficial.
Neoadjuvant TCH + Pertuzumab Linked to Better pCR vs T-DM1 + Pertuzumab in Early Breast Cancer
Neoadjuvant docetaxel plus carboplatin and trastuzumab followed by pertuzumab (TCH+P) was associated with improved pathologic complete response rate .
- Loading...
Loading...
Next post in ASCO 2016
Loading... 
Loading...